290 related articles for article (PubMed ID: 25155604)
1. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
Song I; Borland J; Chen S; Peppercorn A; Wajima T; Piscitelli SC
Antimicrob Agents Chemother; 2014 Nov; 58(11):6696-700. PubMed ID: 25155604
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.
Ford SL; Chen YC; Lou Y; Borland J; Min SS; Yuen GJ; Shelton MJ
Antimicrob Agents Chemother; 2008 Feb; 52(2):534-8. PubMed ID: 18056271
[TBL] [Abstract][Full Text] [Related]
3. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
Song I; Borland J; Chen S; Lou Y; Peppercorn A; Wajima T; Min S; Piscitelli SC
Br J Clin Pharmacol; 2011 Jul; 72(1):103-8. PubMed ID: 21342217
[TBL] [Abstract][Full Text] [Related]
4. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.
Song IH; Borland J; Chen S; Savina P; Peppercorn AF; Piscitelli S
Antimicrob Agents Chemother; 2013 Sep; 57(9):4394-7. PubMed ID: 23817375
[TBL] [Abstract][Full Text] [Related]
5. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
6. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
[TBL] [Abstract][Full Text] [Related]
7. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
Cotton M; Cassim H; Pavía-Ruz N; Garges HP; Perger T; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Sievers J; Cheng K
Pediatr Infect Dis J; 2014 Jan; 33(1):57-62. PubMed ID: 23811743
[TBL] [Abstract][Full Text] [Related]
9. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.
Corbett AH; Patterson KB; Tien HC; Kalvass LA; Eron JJ; Ngo LT; Lim ML; Kashuba AD
Antimicrob Agents Chemother; 2006 Aug; 50(8):2756-61. PubMed ID: 16870769
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.
Shelton MJ; Ford SL; Borland J; Lou Y; Wire MB; Min SS; Xue ZG; Yuen G
J Acquir Immune Defic Syndr; 2006 May; 42(1):61-7. PubMed ID: 16639341
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
Barbour AM; Gibiansky L; Wire MB
J Clin Pharmacol; 2014 Feb; 54(2):206-14. PubMed ID: 25272370
[TBL] [Abstract][Full Text] [Related]
13. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
14. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.
Song I; Borland J; Min S; Lou Y; Chen S; Patel P; Wajima T; Piscitelli SC
Antimicrob Agents Chemother; 2011 Jul; 55(7):3517-21. PubMed ID: 21555764
[TBL] [Abstract][Full Text] [Related]
15. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
Shelton MJ; Wire MB; Lou Y; Adamkiewicz B; Min SS
Antimicrob Agents Chemother; 2006 Mar; 50(3):928-34. PubMed ID: 16495253
[TBL] [Abstract][Full Text] [Related]
17. No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.
Ross LL; Song IH; Arya N; Choukour M; Zong J; Huang SP; Eley T; Wynne B; Buchanan AM
BMC Infect Dis; 2016 Jul; 16():347. PubMed ID: 27450277
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
Pérez-Elías MJ; Morellon ML; Ortega E; Hernández-Quero J; Rodríguez-Torres M; Clotet B; Felizarta F; Gutiérrez F; Pineda JA; Nichols G; Lou Y; Wire MB
Antimicrob Agents Chemother; 2009 Dec; 53(12):5185-96. PubMed ID: 19667283
[TBL] [Abstract][Full Text] [Related]
19. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Kashuba AD; Tierney C; Downey GF; Acosta EP; Vergis EN; Klingman K; Mellors JW; Eshleman SH; Scott TR; Collier AC
AIDS; 2005 Jan; 19(2):145-52. PubMed ID: 15668539
[TBL] [Abstract][Full Text] [Related]
20. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S
Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
